#4 - Merck & Co. (NYSE:MRK)
Merck & Co. Inc. (NYSE: MRK) is another inflation-fighting stock in the pharmaceutical sector. The bullish narrative with Merck centers around its oncology portfolio and its flagship drug, Keytruda which continues to be approved for earlier stage cancers and is experiencing robust global demand from metastatic indications.
However, Keytruda is only one drug in the company’s extensive oncology portfolio. That portfolio is supposed to grow from $10 billion in 2023 to over $20 billion by 2030.
Beyond oncology, Merck has a solid track record of developing innovative medicines covering vaccines, infectious diseases, immunology, and other unmet medical needs. The company has a proven track record of bringing drugs to market while being able to produce solid returns for shareholders. One element of those returns is a dividend that yields over 3.3% in January 2025, has an average annual growth rate of around 5%, and has been increasing for 14 consecutive years.
About Merck & Co., Inc.
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Read More - Current Price
- $96.18
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 12 Buy Ratings, 8 Hold Ratings, 1 Sell Ratings.
- Consensus Price Target
- $123.00 (27.9% Upside)
